{"id":459398,"date":"2021-03-17T06:48:27","date_gmt":"2021-03-17T10:48:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=459398"},"modified":"2021-03-17T06:48:27","modified_gmt":"2021-03-17T10:48:27","slug":"mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/","title":{"rendered":"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health<\/b><\/p>\n<p>KENILWORTH, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Michael T. Nally, chief marketing officer, Human Health, will leave the company at the end of March, and Frank Clyburn, chief commercial officer, Human Health, will become president, Human Health and lead all Human Health commercial and marketing for the company. Nally is leaving Merck for a leadership opportunity with another company.\n<\/p>\n<p>\n\u201cAs our chief marketing officer, Mike has charted ambitious goals for our human health franchises, and has been instrumental in shaping our strategy and ensuring that Merck is well positioned for a successful future,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cMike\u2019s unwavering commitment to Merck\u2019s core values coupled with his inclination to seek new and better ways to meet the needs of today\u2019s patients as well as those we hope to serve in the years ahead have left an enduring mark on Merck, and he will be missed.\u201d\n<\/p>\n<p>\nEffective immediately, Clyburn will become president, Human Health and will lead Human Health marketing and commercial operations with responsibility for the Human Health P&amp;L globally, reporting to Frazier. Starting April 1, 2021, Clyburn will report to Robert M. Davis, current executive vice president, global services and chief financial officer; as previously announced (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fkenneth-c-frazier-to-retire-as-merck-ceo-board-elects-robert-m-davis-as-successor-frazier-to-continue-as-executive-chairman%2F&amp;esheet=52397087&amp;newsitemid=20210317005137&amp;lan=en-US&amp;anchor=link&amp;index=1&amp;md5=9b875e9bb8c4ae2825589cb003c8cc2e\">link<\/a>), Davis will become president of Merck, effective April 1, 2021, at which time the company\u2019s operating divisions \u2013 Human Health, Animal Health, Manufacturing, and Merck Research Laboratories \u2013 will begin reporting to him. Davis will become chief executive officer on July 1, 2021.\n<\/p>\n<p>\n\u201cI have tremendous respect for Frank\u2019s strategic and operational excellence, and believe he is the perfect person to lead our ongoing success in Human Health,\u201d Davis said. \u201cFrank\u2019s leadership in rapidly expanding our oncology footprint and accelerating the growth of that business is unparalleled in our industry, exceeded only by his relentless dedication to helping patients. I look forward to continuing to work with him as we advance Merck\u2019s mission to save and improve lives.\u201d\n<\/p>\n<p>\nClyburn became chief commercial officer for Human Health in January 2019. Prior to this role, Clyburn was the president of Merck\u2019s global oncology business. Clyburn joined Merck in 2008 and has had responsibility for numerous global pharmaceutical franchises, including diabetes, cardiovascular and women\u2019s health, as well as leadership of marketing and sales teams.\n<\/p>\n<p>\nMichael Nally has served as chief marketing officer for Human Health since January 2019, following three years leading Merck\u2019s global vaccines business. Nally has been at Merck since 2003 and served in a number of roles with increasing responsibilities including the managing director of the company\u2019s U.K., Ireland and Sweden markets as well a variety of roles in commercial operations, business development and investor relations.\n<\/p>\n<p><b>About Merck<\/b><\/p>\n<p>\nFor 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals \u2013 including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases \u2013 as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=52397087&amp;newsitemid=20210317005137&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=2&amp;md5=bb3afb108d112a4bbaaed0eda9580824\">www.merck.com<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=52397087&amp;newsitemid=20210317005137&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=45633709e9e88ae5f0261ce67ee97c8c\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=52397087&amp;newsitemid=20210317005137&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=85a8f698c2d5f0c2b458fe883e7b4c3a\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=52397087&amp;newsitemid=20210317005137&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=ff8a1a06b3af946f8cc669cd35ede18a\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=52397087&amp;newsitemid=20210317005137&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=4ea1774765c9b266a2b7667b87830762\">YouTube<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=52397087&amp;newsitemid=20210317005137&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=c150ced812225b2cfa3f6763e3178af2\">LinkedIn<\/a>.\n<\/p>\n<p><b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b><\/p>\n<p>\nThis news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n<p>\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s 2020 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=52397087&amp;newsitemid=20210317005137&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=d7d38aaedd009996b7457659f57a2535\">www.sec.gov<\/a>).\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210317005137\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210317005137\/en\/<\/a><\/span><\/p>\n<p>\nMedia:<br \/>\n<br \/>Patrick Ryan<br \/>\n<br \/>(973) 275-7075\n<\/p>\n<p>\nInvestor:<br \/>\n<br \/>Peter Dannenbaum<br \/>\n<br \/>(908) 740-1037\n<\/p>\n<p>\nRaychel Kruper<br \/>\n<br \/>(908) 740-2107\n<\/p>\n<p><b>KEYWORDS:<\/b> New Jersey United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210317005137\/en\/865613\/3\/02852_Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health KENILWORTH, N.J.&#8211;(BUSINESS WIRE)&#8211; Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Michael T. Nally, chief marketing officer, Human Health, will leave the company at the end of March, and Frank Clyburn, chief commercial officer, Human Health, will become president, Human Health and lead all Human Health commercial and marketing for the company. Nally is leaving Merck for a leadership opportunity with another company. \u201cAs our chief marketing officer, Mike has charted ambitious goals for our human health franchises, and has been instrumental in shaping our strategy and ensuring that Merck is well positioned for a successful future,\u201d said Kenneth C. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-459398","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health KENILWORTH, N.J.&#8211;(BUSINESS WIRE)&#8211; Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Michael T. Nally, chief marketing officer, Human Health, will leave the company at the end of March, and Frank Clyburn, chief commercial officer, Human Health, will become president, Human Health and lead all Human Health commercial and marketing for the company. Nally is leaving Merck for a leadership opportunity with another company. \u201cAs our chief marketing officer, Mike has charted ambitious goals for our human health franchises, and has been instrumental in shaping our strategy and ensuring that Merck is well positioned for a successful future,\u201d said Kenneth C. &hellip; Continue reading &quot;Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-17T10:48:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health\",\"datePublished\":\"2021-03-17T10:48:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/\"},\"wordCount\":944,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/\",\"name\":\"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-17T10:48:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/","og_locale":"en_US","og_type":"article","og_title":"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health - Market Newsdesk","og_description":"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health KENILWORTH, N.J.&#8211;(BUSINESS WIRE)&#8211; Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Michael T. Nally, chief marketing officer, Human Health, will leave the company at the end of March, and Frank Clyburn, chief commercial officer, Human Health, will become president, Human Health and lead all Human Health commercial and marketing for the company. Nally is leaving Merck for a leadership opportunity with another company. \u201cAs our chief marketing officer, Mike has charted ambitious goals for our human health franchises, and has been instrumental in shaping our strategy and ensuring that Merck is well positioned for a successful future,\u201d said Kenneth C. &hellip; Continue reading \"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-17T10:48:27+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health","datePublished":"2021-03-17T10:48:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/"},"wordCount":944,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/","name":"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-17T10:48:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210317005137r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/459398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=459398"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/459398\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=459398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=459398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=459398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}